

Figure 1

ICS component	Conversion Factor (i.e. multiply dose by X)	Minimum acceptable daily dose (mcg)
Fluticasone propionate	1	>250
Fluticasone propionate HFA	1.14	>220 (per actuation)
Fluticasone furoate	2.5	≥100 (metered) ≥92 (delivered)
Budesonide (metered/delivered dose)	0.63/0.78	>400 (metered) >320 (delivered)
Budesonide (nebulized)	0.5	>0.5 mg (2 ml ampules)
Beclomethasone	0.5	>500
Beclomethasone (Trimbow)	1.25	400 (metered) 348 (delivered dose)
Beclomethasone extra-fine particles and HFA (Fostair, QVAR)	1.04 (metered dose) 1.25 (dose per actuation)	>250 (metered dose) >200 (per actuation)
Ciclesonide	1.56	>160
Mometasone furoate	1.14	>220 (metered) >200 (per actuation)
Flunisolide	0.25	>1000
Triamcinolone	0.25	>1000

Sources: GOLD 2018; GINA 2018

ICS component	Conversion Factor (i.e. multiply dose by X)	Minimum acceptable daily dose (mcg)
Budesonide (metered/delivered dose)	0.63/0.78	>400 (metered) >320 (delivered)

Figure 2

SEQ ID NO	Description	Sequence
1	TSLP nucleotide seq	gcagccagaaagctctggagcatcagggagactccaacttaaggcaacagcatgggtgaataagggtctcctgtgactggcaatgagaggcaaaacctgggtgcttgagcactggccctaaaggccttacagatctcttactactcgtgggtggaagagtttagtgaacctgggtggaattgggtgtccacgtatgttcccttttgccttactatatgtctgtcagttcttccaggaaaaacttcatcttcaactttagggctgggtgttaacttaegacttcactaactgtgactttgagaagattaaagcagcctatctcagtaactatttctaagacctgattacatatatgagtgggaccaaagtacogagttcaacaaacacccgtctctttagcaatcgccacattgccttactgaaatccagagcctaacctcaatccccaccgcgctgcgtgcgtcgccaaagaaatgttgcctgaaaactaaggctgccttagctatctgggtgccaggctattcggaacctcagataaaagctactcaggcaatgaagagagagaaaaaggaaagtcaacaaccaataaatgtctggacaagtgtcacaattacaaggatttggcgctcgcttcaatcgacaccttactgaaacaacagtaaacaccatctttattatggtcatatttccacagccccaaaaataaatcatctttattaaagtaaaaaaa aaa
2	TSLP amino acid seq	MFPEALLYLVSVSRKIPILQLVGLVLTYYDFTNCDFEIKAAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTELQSLTENPTAGCSLAKEMFAMTKAALAIWCPGYSETQINATQAMKKRRKRKVITINKCLEQVSQLQGLWRRFNRLLLKQQ
3	Light chain CDR1	GGNLLGSKSVH
4	Light chain CDR2	DDSDRPS
5	Light chain CDR3	QVWDSSSDHVV
6	Heavy chain CDR1	TYGMH
7	Heavy chain CDR2	VIWYDGSNKHYSVKG
8	Heavy chain CDR3	APQWELVHEAFDI
9	VH nucleotide	cagatgcagctggtgagctctggggaggcgtgggtccagcctgggaggtccctgagactctcctgtgcagcgtctggattcaccttcagaacctatggcatgcactgggtccgcagcctccagcaaggactggagtgggtggcagttatatggtatgatggaagtaataaacactatgcagactccgtgaaggccgattcaccatcaccagagacaattccaagaacactctgaatctgcaaatgaacagcctgagcgcggagcacgcggtgtgttactgtgcgagagccctcagtgggagctagtctcatgaagcttttgatatctcggggccaaaggacaaatggtccaccgtctcttcaGGNNLGSKSVHDDSDRPSQVWDSSSDHVVITYGMHVIWYDGSNKHYSVKAPQWELVHEAFDIQWLVESGGGVVQPGRLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWIYDGSNKHYSVKGRFTITRDNSKNTLNLQMN SLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS
10	VH amino acid	

11	VL nucleotide	tcctatgtgtgactcagccaccctcggttcagtgcgccagcagcagccagccagccctgtgctgtctatgatg caaccttggaagtaaaagtgtgcactggtaccagcagcagccagccagccctgtgctgtctatgatg atagcagccggccctcatgcatccctgagcattctctggtctcactctggaacacgcccacctgaccatc agcagggggaagccggggtatgagccgactattactgtcaggtgtgggatagtagtagtgcacatgtggtatt tcggcgaggagaccacgaactgacctccta
12	VL amino acid	SYVLTPPPSVAPGQTARITCGGNLGSKVHWYQQKPGAPVLVYDDSDRPSWIPERFSGNSGNTAII SRGEAGDEADYYCQVWDSSDHVFGGTKLTVL
13	Full length heavy, CDRs underlined	QMQLVESGGG VVQGRSIRL SCAASGFTF <u>TYGMHWVRQA</u> PKGLEWVAV <u>IWYDGSNKHY</u> ADSVKGRFTI TRDNSKNTLN LQMSLRAED TAVYYCARAP <u>QWELVHEAFD</u> IWGQTMVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPTV <u>VSWNSGALTS</u> GVHFFPAVLQ SSGLYSLSV VTPSSNFGT <u>QTYTCNVVDHK</u> PSNTKVDKTV ERKCCVECPP CPAPPVAGPS VFLPPKPKD TLMISRTPEV <u>TCVVVDVSHE</u> DPEVQFNWYV DGVEVHNAKT KPREEQFNST FRVSVLTIV HQDWLNGKEY KCKVSNKGLP APIEKTISKT KGQPREPQVY TLPFSREEMT KNQVSLTCLV KGFYPSDIAV EMESNGQPEN NYKTTTPMMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
14	Full length light, CDRs underlined	SYVLTPPPSV SVAPGQTARI TCGGNLGSK SVHWYQQKPG QAPVLVVYDD SDRPSWIPER FSGNSGNTA TLTISRGEAG DEADYYCQVW DSSSDHVVFG GGTKLTVILGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS

Figure 2 continued

Figure 3

Subject characteristic	Statistics or category	Teze 420 mg Q4W (N=165)	Placebo (N=168)	Total (N=333)
Body Mass Index* (kg/m²)				
n		165	168	333
Mean		27.27	27.36	27.32
SD		5.720	6.430	6.080
Median		27.11	26.50	26.90
Baseline blood eosinophil count (cells/µL)				
n		165	168	333
Mean		195.2	214.9	205.2
SD		132.86	161.99	148.38
Median		150.0	180.0	170.0
Baseline blood eosinophil count group (cells/µL) n (%)				
<150		73 (44.2)	64 (38.1)	137 (41.1)
>=150 - <300		68 (41.2)	72 (42.9)	140 (42.0)
>=300		24 (14.5)	32 (19.0)	56 (16.8)
Baseline FeNO (ppb)				
n		143	142	285
Mean		17.7	19.0	18.3
SD		13.35	14.40	13.87
Median		14.0	15.0	15.0
Baseline clinic visit FeNO group 2 (ppb) n (%)				
<25		117 (81.8)	109 (76.8)	226 (79.3)
>=25 - <50		20 (14.0)	29 (20.4)	49 (17.2)
>=50		6 (4.2)	4 (2.8)	10 (3.5)
Diagnosis of emphysema n (%)				
Yes		91 (55.2)	101 (60.1)	192 (57.7)
No		74 (44.8)	67 (39.9)	141 (42.3)
Diagnosis of obstructive chronic bronchitis n (%)				
Yes		85 (51.5)	100 (59.5)	185 (55.6)
No		80 (48.5)	68 (40.5)	148 (44.4)

Figure 4




Figure 4 continued




Figure 5

			Annual exacerbation rate				Rate ratio	
Treatment group	n	Number of events	Time at-risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI
Teze 420 mg Q4W (N=165)	165	19	156.2	0.12	0.13	(0.07, 0.24)	0.52	(0.24, 1.11)
Placebo (N=168)	168	34	156.3	0.22	0.25	(0.15, 0.42)		
								2-sided p-value
								0.0911

n represents the number of subjects included in analysis.
Primary estimand: Include all observed data over the 52-week period regardless of whether subjects remain on randomized treatment and regardless of whether subjects switch to an alternative biologic treatment.

Figure 6

Change from Baseline at Week 52	Treatment Group	n	Change from baseline			Comparison with Placebo		
			LSMean	SE	LSMean difference	95% CI	p-value	
Pre-BD FEV1	Taze 420 mg Q4W (N=165)	163	0.026	0.015	0.055	(0.014, 0.096)	0.0094	
	Placebo (N=168)	166	-0.029	0.015				
SGRQ Total Score	Taze 420 mg Q4W (N=165)	157	-4.796	1.176	-2.933	(-6.227, 0.361)	0.0907	
	Placebo (N=168)	156	-1.863	1.189				
CAT Total Score	Taze 420 mg Q4W (N=165)	159	-3.037	0.524	-1.855	(-3.314, -0.395)	0.0129	
	Placebo (N=168)	162	-1.182	0.524				
E-RS™ Total Score	Taze 420 mg Q4W (N=165)	165	-0.912	0.343	-0.351	(-1.303, 0.601)	0.4691	
	Placebo (N=168)	167	-0.561	0.343				

n=Number of subjects contributing to the analysis, i.e. the number of subjects with at least one change from baseline value at any post baseline visit.

Figure 7

Eos at BL	Change from Baseline at Week 52	Treatment Group	n	Change from baseline		Comparison with Placebo		
				LSMean	SE	LSMean difference	95% CI	p-value
EoS <150	Pre-BD FEV1	Teze 420 mg Q4W (N=73)	73	-0.002	0.022	0.051	(-0.012, 0.114)	0.1124
		Placebo (N=64)	63	-0.052	0.023			
EoS ≥150- <300	Pre-BD FEV1	Teze 420 mg Q4W (N=68)	66	0.010	0.023	0.034	(-0.028, 0.097)	0.2808
		Placebo (N=72)	72	-0.025	0.022			
EoS ≥300	Pre-BD FEV1	Teze 420 mg Q4W (N=24)	24	0.160	0.038	0.146	(0.044, 0.288)	0.0050
		Placebo (N=32)	31	0.013	0.035			
EoS <150	SGRQ Total Score	Teze 420 mg Q4W (N=73)	60	-1.912	1.751	-1.619	(-6.691, 3.454)	0.5305
		Placebo (N=64)	53	-0.294	1.891			
EoS ≥150- <300	SGRQ Total Score	Teze 420 mg Q4W (N=68)	57	-6.046	1.809	-2.407	(-7.361, 2.547)	0.3398
		Placebo (N=72)	62	-3.639	1.752			
EoS ≥300	SGRQ Total Score	Teze 420 mg Q4W (N=24)	19	-10.215	3.140	-9.532	(-18.105, -0.959)	0.0294
		Placebo (N=32)	19	-0.683	3.012			

Figure 8

EOS

Timepoint	Mean Teze (SD)	Mean CFB Teze (SD)	Mean Pbo (SD)	Mean CFB Pbo (SD)
Baseline	191.8 (127.79)	NA	215.3 (162.06)	NA
Week 12	123.5 (78.12)	-64.6 (117.26)	183.0 (113.41)	-33.4 (131.80)
Week 24	111.9 (75.67)	-81.7 (121.77)	178.8 (126.37)	-27.4 (147.74)
Week 36	123.3 (88.29)	-70.6 (120.20)	188.6 (118.84)	-15.7 (148.42)
Week 52	110.3 (68.16)	-83.3 (108.40)	185.7 (113.60)	-20.7 (147.65)

FeNO

Timepoint	Mean Teze (SD)	Mean CFB Teze (SD)	Mean Pbo (SD)	Mean CFB Pbo (SD)
Baseline	17.7 (13.35)	NA	19.0 (14.40)	NA
Week 12	15.9 (11.28)	-3.2 (9.98)	18.2 (11.44)	0.7 (10.24)
Week 24	15.1 (10.24)	-3.7 (13.38)	18.7 (11.33)	-0.2 (10.86)
Week 36	16.4 (11.49)	-3.5 (13.24)	18.8 (13.43)	-0.4 (11.10)
Week 52	13.8 (9.05)	-5.4 (13.87)	18.0 (13.23)	-0.2 (11.41)

Figure 8 continued

Neutrophils

Timepoint	Mean Teze (SD)	Mean CFB Teze (SD)	Mean Pbo (SD)	Mean CFB Pbo (SD)
Baseline	5.011 (1.5757)	NA	5.456 (2.1136)	NA
Week 12	5.035 (1.5239)	-0.044 (1.6114)	5.516 (2.0881)	0.143 (2.1108)
Week 24	5.152 (1.7195)	0.109 (1.7238)	5.195 (1.9499)	-0.229 (2.1630)
Week 36	4.781 (1.7511)	-0.232 (1.6538)	5.208 (1.9449)	-0.176 (1.9544)
Week 52	5.322 (1.9011)	0.331 (1.8847)	5.414 (1.8981)	-0.033 (2.0339)